Messenger services
– Free Small Business Ideas Winweb online office
Marketing Strategy Search Engine Optimization Slide8
src = “http://farm4.static.flickr.com/3078/2591926442_f2cd790e87.jpg”
Image hongxing128
20px 10px 0 style = “float: left; margin: 
Sandy Hook, CT (NYSE) 27 September 2011
Trevi Therapeutics, Inc. announces its formation and early development of the T111 for chronic uremic pruritus. The company is seeking orphan drug status for this connection in the U.S. and Europe, but also methods patent applications.
Trevi was founded in 2011 as a development of drugs to the development of compounds, especially for rare diseases with unmet medical needs focused. The company was co-founded by Jennifer L. Good and Thomas R. Sciascia, MD, senior management team earlier in Penwest Pharmaceuticals, which was acquired by its partner, Endo Pharmaceuticals in the fourth quarter of 2010. Ms. Good served as president of Trevi? S, will be CEO and Dr. Sciascia, there to serve the society? S Medical Director.
lead compound Trevi? s, T111 occurs in Phase 2 development and is aligned in the treatment of chronic uremic pruritus, a persistent itch in hemodialysis patients. Currently there are no pharmacological treatments approved in the U.S. or Europe for chronic uremic pruritus, which assumes the company, there are approximately 170,000 patients in the United States and 135,000 patients in Europe.
? Trevi? s development strategy reflects our belief in the value against the development of orphan drugs? Mrs. Good said. ? There are huge unmet needs in rare diseases, and we believe that small businesses focused on the development of drugs such as Trevi are the best, these compounds efficiently at the points of proof of concept and value creation ahead. We have worked very diligently to begin the steps necessary to begin clinical trials that we intend, in the first quarter of 2012 to complete.
About Trevi
??Therapeutics, Inc.
Trevi
Therapeutics, Inc. is a drug development company founded in 2011 to develop links, particularly for rare diseases with high unmet medical need. The main component of the company? S, T111 occurs in Phase 2 development and is in the treatment of chronic uremic pruritus, a persistent itch in patients receiving dialysis should. The company strives to Orphan Drug Designation in the U.S. and Europe and processing patent applications. The company also intends to evaluate opportunities for other orphans, adding to their development portfolio. For more information, visit http://www.trevitherapeutics.com.
###